Bladder cancer breakthrough? drug combo aims to stop tumors returning
NCT ID NCT05327647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug bicalutamide to standard BCG therapy can help prevent bladder tumors from returning in men with non-muscle invasive bladder cancer. About 160 participants will be randomly assigned to receive either BCG alone or BCG plus bicalutamide. The main goal is to see if the combination delays or reduces cancer recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Males, age 18 or greater. 2. Patients with histologically confirmed non-muscle invasive urothelial carcinoma. 3. Patients have been recommended for a course of intravesical BCG induction treatment by their urologist 4. Patients who received gemcitabine, epirubicin or mitomycin C instillations immediately post-operatively will be eligible for enrollment. 5. Patients with partners of child-bearing potential must agree to 2 acceptable forms of birth control and be continued for at least 3 months after study drug is discontinued. Exclusion Criteria: 1. Patients who have received induction BCG therapy within the last 5 years will be ineligible for enrolment. 2. Patients with a history of myocardial infarction or hospital admission for heart failure within the previous 12 months or who have unstable cardiovascular status will be ineligible for enrolment. 3. Patients who have uncontrolled hypertension (for our purposes, defined as those having a systolic blood pressure \> 160 documented on 2 occasions despite appropriate medical therapy) will similarly be ineligible. 4. Patients with a history of liver disease whose hepatic enzymes, alkaline phosphatase or bilirubin are greater than twice the upper limit of normal will be ineligible. 5. Patients with clinical hypogonadism, those on androgen replacement therapy, or those with prostate cancer or other diseases treated with systemic hormonal therapy will be ineligible for study enrolment. Patients receiving 5ARIs will not be excluded. 6. Patients who have cancer treatment ongoing or planned in the near future which can be anticipated to decrease their 2-year survival or BCa treatment plan will be ineligible. 7. Patients taking an investigational drug within 2 weeks of enrolment into this study will be ineligible. 8. Patients receiving or planning to receive coumadin therapy will be ineligible.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-muscle invasive bladder cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Québec-Université Laval
RECRUITINGQuébec, Quebec, G1G 5X1, Canada
-
CIUSSS de l'Estrie - CHUS
RECRUITINGSherbrooke, Quebec, J1H 5H3, Canada
-
Centre Hospitalier de l'Université De Montréal_CHUM
RECRUITINGMontreal, Quebec, H2X 3E4, Canada
-
Centre intégré de santé et services sociaux de Chaudière Appalaches
RECRUITINGLévis, Quebec, G6V3Z1, Canada
-
London Health Sciences Centre
RECRUITINGLondon, Ontario, N6A 5W9, Canada
-
McGill University Health Centre_CUSM
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
-
University Health Network, Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2C1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dutch bladder cancer cohort aims to map survival and recurrence
- Lab-Grown tumor organoids could pick the right bladder chemo
- Can heated saline during bladder surgery stop tumors from coming back?
- Radiation instead of bladder removal: a new option for Hard-to-Treat bladder cancer?
- Can an immunotherapy plus chemotherapy keep High-Risk bladder cancer at bay?
- Can a bladder rinse before surgery keep bladder cancer at bay?